FINARO
Finaro (tidligere Credorax) , en global betalingsudbyder og Europæisk bank, der styrker international handel gennem teknologiske og enkle betalingsløsninger, har i dag offentliggjort, at de har indgået en aftale med Shift4 omkring salget af Finaro til en værdi af 575 millioner USD. Det kombinerede tilbud, fra begge virksomheder, skaber en positiv synergi af et globalt betalingsnetværk med en betydelig POS og eCommerce platform, på tværs af en bred vifte af vertikaler, der servicerer store og komplekse virksomheder med unikke løsninger. Sammen vil Finaro og Shift4 være bedre i stand til at forsyne virksomheder med globale betalingsløsninger gennem flere kanaler, og stå side om side med nogle af de største aktører i betalingsbranchen, heriblandt Adyen, Nuvei og WorldPay.
“Dette køb understreger vores offensive bestræbelser på, at levere en unified commerce oplevelse overalt i verden. Denne handel viser tydeligt vores evne til at støtte eksisterende transformerende og globale kunder, såsom SpaceX Starlink & St. Jude Children’s Research Hospital,” fortæller Shift4s CEO Jared Isaacman.
Finaro vil levere den globale infrastruktur og den nødvendige banebrydende teknologi, for at føre Shift4s internationale ambitioner ud i livet om at levere en unified commerce løsning. Ved at integrere Finaros kapaciteter, vil Shift4 være i stand til at udvide virksomhedens nuværende serviceydelser overalt i verden, inklusiv dens næste generation af SkyTab POS-løsning, Shift4Shop e-handelsplatform og VenueNext stadiontilbud. Shift4 har også mere end 425 softwareintegrationer og over 200.000 merchants, hvoraf mange har en multinational tilstedeværelse, og giver øjeblikkelige internationale muligheder, som der nu kan åbnes for som et resultat af denne nyerhvervelse.
“Denne erhvervelse understreger, at vi har opnået, hvad vi har sat os for at opnå – at opbygge pålidelige betalingsbehandlingskapaciteter, som i sandhed er uden grænser, både hvad angår tilgængelighed og størrelse. At kunne anvende denne teknologi til SpaceXs Starlink-program, og andre der er tilsvarende i størrelsen, samtidig med også at kunne tilbyde vores virksomheder og partnere overalt i verden et bredere udvalg af produkter og serviceydelser, er realiseringen af dette mål på den mest konkrete måde, og vi er begejstrede over at blive en del af Shift 4- teamet,” fortæller Igal Rotem, CEO for Finaro.
For yderligere information om denne nyerhvervelse, besøg venligst præsentationssektionen på Shift4s Investor Relations website her .
###
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220311005243/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum